Johnson & Johnson Ad26 adenovirus vector COVID-19 vaccine less effective than other vaccines

Johnson & Johnson Ad26 adenovirus vector COVID-19 vaccine less effective than other vaccines.   In view of the current global epidemic situation is getting more serious but vaccines are slightly tense, the more safe and effective vaccines, the more we should be happy.

28 days after the Johnson & Johnson Ad26 adenovirus vector COVID-19 vaccination, the overall protective effect of preventing moderate to severe new coronaviruspneumonia is 66%.

The preventive effect was observed as early as the 14th day. 28 days after vaccination, the level of protection against moderate to severe COVID-19 infection is:

• 72% in the United States,
• 66% in Latin America,
• 57% in South Africa.

Moderate to severe is the protective effect for the severity of new coronavirus pneumonia at levels 4-9. If level 1 (asymptomatic infection), level 2 (slight symptoms do not need help), and level 3 (symptoms, need help) are counted as possible data In some people’s opinion, it will be more hip.

Overall, this result may be inferior to the inactivated vaccine produced in China (77.98% for ≤3 grade, 100% for ≥4 grade), and the preventive effect observed on the 14th day is actually not as good as the mRNA vaccine (prevention observed on the 10th day) However, there is a problem that needs to be considered. This is only a single injection of protection. Based on the information of Ad25 in the United Kingdom, 2 doses of vaccination should induce a better immune response, so whether there will be more data in the future is still needed Wait and see.

But on the whole, one more vaccine is one more weapon against the COVID-19 epidemic, especially for the current global epidemic situation when the vaccine is slightly tense. The more safe and effective vaccines, the more we are happy.

(source:internet, reference only)

Disclaimer of medicaltrend.org